Gamma Medica Launches Be Certain Campaign to Educate Women on Dense Breast Tissue
SALEM, N.H.–(BUSINESS WIRE)–Gamma
Medica, a leader in molecular breast imaging technology (MBI),
announced today it has launched the Be Certain campaign,
featuring a dedicated microsite
as the cornerstone of an initiative to spread awareness on breast
density. Today, about half of all women in the United States have dense
breast tissue, making them four to five times1 more likely to
develop breast cancer. Traditional screening technology alone is not
advanced enough to accurately detect cancerous tumors for these women
who have a higher intrinsic risk of developing cancer during the course
of their lifetime.
The goal of the campaign is to confront the 40,000 deaths annually at
the hands of breast cancer by empowering women to be proactive about
their breast health and consult their doctors to gain a better
understanding of risks associated with dense breast tissue. The
microsite provides patients with a one-stop educational resource with
the most updated, accurate information for women with dense breast
tissue, allowing them to Be Certain about their screening results
and the latest clinical data on breast cancer.
With the Be Certain campaign, Gamma Medica aims to shift the
public conversation on breast cancer awareness by educating patients,
physicians, breast surgeons, radiologists and the industry about how MBI
can increase detection rates by 400 percent2 and offer other
benefits when used as a supplemental screening tool to the traditional
mammogram. Visitors will have access to accurate information and
statistics, testimonials and patient stories.
“Here at Gamma Medica, our goal is to educate patients and providers
about dense breast tissue and the challenges and limitations of today’s
current standard of care to provide comprehensive and accurate cancer
screening results that can be served with clinically, proven
supplemental technology,” said Philip Croxford, CEO of Gamma Medica.
“MBI is a reliable alternative that has proven to increase the detection
of six more cancers missed by mammography in women with dense breast
tissue. We believe all women should expect a personalized care plan for
their own clinical situation and access to the latest information that
will empower them to make the best-informed choice about their
diagnostics and treatment plans. The Be Certain campaign is a
major step forward in education about dense breast tissue with an
informed and balanced approach that can be trusted as reliable and
accurate.”
About Gamma Medica, Inc.
Gamma Medica, Inc. is a women’s
health company focused on overcoming the limitations of anatomical
imaging experienced by mammography and other screening modalities in the
early detection of breast cancer. The company’s LumaGEM® MBI system is
the first commercially available, FDA-cleared, fully solid-state digital
imaging system utilizing dual-head Digital Direct Conversion Gamma
Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90
percent sensitivity and specificity, LumaGEM MBI has been shown to
significantly improve cancer detection in women with dense breast tissue
with fewer false positives relative to anatomical imaging technologies,
such as MRI and whole breast ultrasound. 3 For more
information visit, www.gammamedica.com.
1 Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the
risk and detection of breast cancer. N Engl J Med. 356(3):227-36, 2007.
2
Rhodes DJ, Hruska CB, Conners AL, et al.
JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for
Supplemental Screening in Mammographically Dense Breasts. American
Journal of Roentgenology. 2015;204(2):241-251.
3 Rhodes
DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB:
Molecular Breast Imaging at Reduced Radiation Dose for Supplemental
Screening in Mammographically Dense Breasts. American Journal of
Roentgenology. 2015;204(2):241-251.
Contacts
Media Contact:
Racepoint Global
Tara Kadioglu,
617-624-3239
tkadioglu@racepointglobal.com
